CollPlant Biotechnologies Ltd(CLGN)Stock Analysis

CLGN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for CollPlant Biotechnologies Ltd (CLGN), a Healthcare sector company. CLGN is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $15.6m in revenue. Based on the latest XBRL financial filings (FY 2025), CollPlant Biotechnologies Ltd reports quarterly revenue of $2.4M, net income of $-11.5M, free cash flow of $-9.4M. Top institutional holders of CLGN by reported 13-F value include VILLERE ST DENIS J & CO, PINNACLE ASSOCIATES LTD, BROWN ADVISORY, based on the most recent SEC filings. CLGN trades on the Nasdaq exchange and files with the SEC under CIK 1631487. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CLGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CollPlant Biotechnologies Ltd directly from SEC EDGAR.